Skip to main content
. 2015 Feb 3;19(1):32. doi: 10.1186/s13054-015-0753-8

Table 4.

Probability of pharmacodynamic target attainment

C. albicans C. glabrata C. krusei C. parapsilosis C. tropicalis A. fumigatus A. niger A. terreus
Pfizer
4 mg/kg q12h fAUC/MIC >25 99.9 86.3 97.9 99.5 99.6 97.1
fAUC/MIC >35 99.8 81.6 94.8 99.2 99.3 92.8
6 mg/kg q12h fAUC/MIC >25 99.9 90.0 99.1 99.7 99.8 99.2
fAUC/MIC >35 99.8 86.8 98.3 99.6 99.6 97.9
EUCAST
4 mg/kg q12h fAUC/MIC >25 99.2 90.3 77.2 60.5
fAUC/MIC >35 99.1 80.3 61.9 41.6
6 mg/kg q12h fAUC/MIC >25 99.4 96.3 91.7 81.4
fAUC/MIC >35 99.2 92.1 80.3 65.4
8 mg/kg q12h fAUC/MIC >25 96.4 89.5
fAUC/MIC >35 90.6 79.0
10 mg/kg q12h fAUC/MIC >25 98.6 94.1
fAUC/MIC >35 95.4 86.1
12 mg/kg q12h fAUC/MIC >25 96.6
fAUC/MIC >35 90.6
CLSI
4 mg/kg q12h fAUC/MIC >25 99.1 89.1 94.1 99.6 98.0
fAUC/MIC >35 99.0 86.0 88.1 99.3 97.7
6 mg/kg q12h fAUC/MIC >25 99.6 92.9 98.0 99.7 98.0
fAUC/MIC >35 99.5 89.9 95.3 99.6 97.9

Data reported as % of patients obtaining target fAUC/MIC ratio at the prescribed dose. Data not available for every organism within all databases. fAUC0-12, free area under the concentration-time curve from 0 to 12 hours; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; CLSI, Clinical and Laboratory Standards Institute.